13:22:34 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


ListaMERK Equities
PatientSky Group är ett norskt bolag verksamma inom teknikbranschen. Bolaget är specialiserade inom utveckling av mjukvarulösningar. Programvaran är egenutvecklad och används huvudsakligen inom vård och omsorg för uppföljning och analys. Utöver huvudverksamheten erbjuds diverse mervärdestjänster. Störst verksamhet återfinns inom den nordiska marknaden.


2022-11-11 Kvartalsrapport 2022-Q3
2022-08-15 Kvartalsrapport 2022-Q2
2022-05-20 Kvartalsrapport 2022-Q1
2022-02-22 Bokslutskommuniké 2021
2021-10-13 Extra Bolagsstämma 2021
2021-09-01 Kvartalsrapport 2021-Q2
2021-06-11 Ordinarie utdelning PSKY 0.00 NOK
2021-06-10 Årsstämma 2021
2021-05-14 Bokslutskommuniké 2020
2020-12-09 23:04:17

Oslo, Norway, 9 December 2020
Reference is made to the stock exchange announcement from PatientSky Group AS
("PatientSky" or the "Company") published on 9 December 2020 regarding a
contemplated private placement of new shares.

The Company announces today that it has raised NOK 350 million in gross proceeds
through a private placement (the "Private Placement") of 25,000,000 new shares
in the Company (the "Offer Shares"), at a price per Offer Share of NOK 14.00 The
offer price represents a discount of 6.4% to the volume weighted average price 9
December 2020.

The Private Placement took place through an accelerated bookbuilding process
managed by Carnegie AS and DNB Markets, a part of DNB Bank ASA as Joint
Bookrunners (together the "Managers") after close of markets on 9 December 2020.
The Private Placement received strong interest from high quality institutional
investors in the Nordics and internationally.

The net proceeds from the Private Placement will be used for further growth
initiatives, including:
- Continue to pursue attractive M&A opportunities, including exploring potential
acquisitions of international targets which can broaden the group's offering and
international footprint
- Scaling the organization both geographically and within all business segments,
by benefiting from the strong present momentum
- Excel on the potential outcome of the dialogues with high potential PaaS

Notification of allocation and payment instructions is expected to be submitted
to the applicants on or about 10 December 2020 by the Managers. The Offer Shares
allocated in the Private Placement will be settled through a delivery versus
payment transaction on a regular T+2 basis on or about 14 December 2020 by
delivery of existing and unencumbered shares in the Company that are already
listed on Euronext Growth Oslo pursuant to a share lending agreement between
Carnegie AS (acting on behalf of the Managers), the Company and Codee Holding
AS. The shares delivered to the applicants are thus tradable from allocation.
Carnegie AS will settle the share loan with new shares in the Company resolved
issued by the board of directors pursuant to an authorisation granted by the
extraordinary general meeting of the Company held on 19 October 2020 (as
registered in the Norwegian Register of Business Enterprises on 20 October
2020). Following registration of the share capital increase pertaining to the
Private Placement with the Norwegian Register of Business Enterprises, the
Company will have a share capital of NOK 27,315,914.51, divided into 198,862,687
shares, each with a par value of NOK 0.137360683.
The Offer Shares issued are expected to commence trading on Euronext Growth Oslo
on or about the date of the said registration.

The Company's existing 6-month lock-up undertaking applicable from first day of
trading of the Company's shares on Euronext Growth Oslo on 23 October 2020 with
respect to issuing new shares has been replaced by a similar lock-up undertaking
from the Company in favour of the Managers applicable for a period 6 months from
the date of completion of the Private Placement.

The Private Placement represents a deviation from the shareholders' pre-emptive
right to subscribe for the Offer Shares. The board of directors has carefully
considered the Private Placement in light of the requirements in the Norwegian
Private Limited Companies Act and the rules of equal treatment set out in the
Continuing obligations for companies admitted to trading on Euronext Growth and
Oslo Børs' guidelines on the rules of equal treatment. The board of directors
has in this respect inter alia taken into consideration that (i) the Company
needs swift funding to pursue and accelerate its growth strategy, to take
advantage of the current momentum and to strengthen its balance sheet after the
recent acquisition of Infodoc AS, and that the Private Placement allows the
Company to utilize the current favourable market conditions, (ii) the Private
Placement will strengthen the Company's shareholder base, (iii) the offer price
in the Private Placement represented a limited discount to volume weighted
average price, (iv) the size of the Private Placement is within the existing
authorization granted to the board of directors, (v) the Private Placement was
publicly announced prior to the bookbuilding process, (vi) it would be costly
and time consuming to carry out a rights issue and slow the growth plans, (vii)
the offer price has been set based on a pre-sounding exercise and a broad
bookbuilding process and can therefore be assumed to express the market price
for the relevant number of shares in the Company, and (viii) shareholders of the
Company can offset the dilutive effect by acquiring shares in the market. The
board of directors has concluded that the Private Placement is in compliance
with said equal treatment requirements, and resolved to not implement any
subsequent offering.

Advokatfirmaet Thommessen AS is acting as legal advisor to the Company in
connection with the Private Placement and Advokatfirmaet Wiersholm AS is acting
as legal advisor to the Managers in connection with the Private Placement.

For further information, please contact:

Johan Zetterström | CEO
E-mail: jz@patientsky.com |Tel: +46 708296611

John Edminson | CFO
E-mail: john.edminson@patientsky.com | Tel: + 47 952 16 162

About PatientSky

PatientSky, founded in 2014 to innovate e-health, is a cloud-based SaaS
(Software as a Service), PaaS (Platform as a Service) and IaaS (Infrastructure
as a Service) company delivering solutions to the health care industry (both
practitioners and patients). The Group's main products are the PatientSky 360
Platform and EHR systems, including other similar administration services. At
the core of the Group's business is the PatientSky 360 Platform, which is a
platform that provides all the necessary building blocks for rapid development
of highly scalable healthcare software. PatientSky has an open platform and EHR
system, enabling an ecosystem in which healthcare providers can communicate with
each other using one system, and in which data can be aggregated and consumed on
a higher level.

Important information

This announcement is not and does not form a part of any offer to sell, or a
solicitation of an offer to purchase, any securities of the Company. Copies of
this announcement are not being made and may not be distributed or sent into any
jurisdiction in which such distribution would be unlawful or would require
registration or other measures.

The securities referred to in this announcement have not been and will not be
registered under the U.S. Securities Act of 1933, as amended (the "Securities
Act"), and accordingly may not be offered or sold in the United States absent
registration or an applicable exemption from the registration requirements of
the Securities Act and in accordance with applicable U.S. state securities laws.
The Company does not intend to register any part of the offering in the United
States or to conduct a public offering of securities in the United States. Any
sale in the United States of the securities mentioned in this announcement will
be made solely to "qualified institutional buyers" as defined in Rule 144A under
the Securities Act.
In any EEA Member State, this communication is only addressed to and is only
directed at qualified investors in that Member State within the meaning of the
Prospectus Regulation, i.e., only to investors who can receive the offer without
an approved prospectus in such EEA Member State. The expression "Prospectus
Regulation" means Regulation (EU) 2017/1129 as amended (together with any
applicable implementing measures in any Member State.

This communication is only being distributed to and is only directed at persons
in the United Kingdom that are (i) investment professionals falling within
Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005, as amended (the "Order") or (ii) high net worth entities,
and other persons to whom this announcement may lawfully be communicated,
falling within Article 49(2)(a) to (d) of the Order (all such persons together
being referred to as "relevant persons"). This communication must not be acted
on or relied on by persons who are not relevant persons. Any investment or
investment activity to which this communication relates is available only for
relevant persons and will be engaged in only with relevant persons. Persons
distributing this communication must satisfy themselves that it is lawful to do

Matters discussed in this announcement may constitute forward-looking
statements. Forward-looking statements are statements that are not historical
facts and may be identified by words such as "believe", "expect", "anticipate",
"strategy", "intends", "estimate", "will", "may", "continue", "should" and
similar expressions. The forward-looking statements in this release are based
upon various assumptions, many of which are based, in turn, upon further
assumptions. Although the Company believe that these assumptions were reasonable
when made, these assumptions are inherently subject to significant known and
unknown risks, uncertainties, contingencies and other important factors which
are difficult or impossible to predict, and are beyond their control. Actual
events may differ significantly from any anticipated development due to a number
of factors, including without limitation, changes in public sector investment
levels, changes in the general economic, political and market conditions in the
markets in which the Company operates, the Company's ability to attract, retain
and motivate qualified personnel, changes in the Company's ability to engage in
commercially acceptable acquisitions and strategic investments, and changes in
laws and regulation and the potential impact of legal proceedings and actions.
Such risks, uncertainties, contingencies and other important factors could cause
actual events to differ materially from the expectations expressed or implied in
this release by such forward-looking statements. The Company does not make any
guarantee that the assumptions underlying the forward-looking statements in this
announcement are free from errors nor does it accept any responsibility for the
future accuracy of the opinions expressed in this announcement or any obligation
to update or revise the statements in this announcement to reflect subsequent
events. You should not place undue reliance on the forward-looking statements in
this announcement. The information, opinions and forward-looking statements
contained in this announcement speak only as at its date, and are subject to
change without notice. The Company does not undertake any obligation to review,
update, confirm, or to release publicly any revisions to any forward-looking
statements to reflect events that occur or circumstances that arise in relation
to the content of this announcement.

Neither the Managers nor any of their affiliates makes any representation as to
the accuracy or completeness of this announcement and none of them accepts any
responsibility for the contents of this announcement or any matters referred to
herein. This announcement is for information purposes only and is not to be
relied upon in substitution for the exercise of independent judgment. It is not
intended as investment advice and under no circumstances is it to be used or
considered as an offer to sell, or a solicitation of an offer to buy any
securities or a recommendation to buy or sell any securities of the Company.
Neither the Managers nor any of its affiliates accepts any liability arising
from the use of this announcement. The distribution of this announcement and
other information may be restricted by law in certain jurisdictions. Persons
into whose possession this announcement or such other information should come
are required to inform themselves about and to observe any such restrictions.